

Special Issue

Multi-Drug Resistant Gram-Negative Infections: Molecular Epidemiology, Microbiological Diagnosis, and Antimicrobial Treatment, 2nd Edition

Message from the Guest Editor

Multi-drug resistant Gram-negative bacilli represent a serious threat among antimicrobials resistances. MDR-GNB are resistant to multiple antimicrobial molecules, thus reducing the antimicrobial options available for treating infections sustained by these microorganisms. To counteract the paucity of the antimicrobial molecules for the treatment of infections due to MDR-GNB, multidisciplinary approaches are required. Innovative strategies for diagnosis, infection control and antimicrobial stewardship are the key factors. In this Special Issue, we invite authors to send in their manuscripts on the following areas of interest:

- Novel in vitro diagnostic tools for MDR-GNB detection and antimicrobial susceptibility testing;
- The molecular epidemiology of Gram-negative pathogens and resistance mechanisms;
- The evaluation of antimicrobial treatment regimens for MDR-GNB;
- New drugs against MDR-GNB: clinical use, in vitro susceptibility testing and emerging resistance.
- Pharmacodynamics/pharmacokinetics parameter to optimise antimicrobial treatments for MDR-GNB

Guest Editor

Dr. Paolo Gaibani

Department of Diagnostics and Public Health, Section of Microbiology,
University of Verona, Verona, Italy

Deadline for manuscript submissions

31 August 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/232193

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)